Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pimicotinib DDI Study with Metformin, Fexofenadine and Rosuvastatin
NCT06779253Phase 1Completed
- Sponsor
- Abbisko Therapeutics
- Start
- Mar 2025
- Primary completion
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pimicotinib in tenosynovial giant cell tumor (TGCT), sponsored by Abbisko Therapeutics. Primary endpoints: Maximum Plasma Concentration at 120 hours, Area Under the Plasma Concentration-Time Curve from Time Zero to Last Quantifiable Concentration at 120 hours and 1 more. Started Mar 2025; status: completed.
02
Drugs
pimicotinib
03
Conditions
tenosynovial giant cell tumor (TGCT)
Beyond the preview
Go deeper on NCT06779253.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06779253.